Wissenschaftliche Arbeiten

Doç. Dr. Özgen Ahmet Yıldırım

38 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study

    Medicina, 2026

    DOI 10.3390/medicina62040763 PMID 42075632 Frei zugänglicher VolltextQuelle: ORCID

  2. Level II (IIA/IIB) Lymph Node Evaluation in Head and Neck Cancer: A Retrospective Cohort Study from a Non-Endemic Region

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15031068 PMID 41682748 Frei zugänglicher VolltextQuelle: ORCID

  3. Exploring the impacts of docetaxel and paclitaxel based neoadjuvant therapies on early postoperative complications in HER2-positive breast cancer patients

    World journal of surgical oncology, 2026

    DOI 10.1186/s12957-026-04434-z PMID 42192428 Frei zugänglicher VolltextQuelle: Europe PMC

  4. Claudin 18.2 Positivity Thresholds and Candidate Populations for Targeted Therapy in Pancreatic Ductal Adenocarcinoma: A Real-World Retrospective Cohort

    Cancers, 2026

    DOI 10.3390/cancers18172827 PMID 42738347 Frei zugänglicher VolltextQuelle: OpenAlex

  5. Structural Acceleration in Sepsis-Associated Cancer Mortality in an Aging Population: A Nationwide Study in the United States, 1999–2020

    SSRN Electronic Journal, 2026

    DOI 10.2139/ssrn.6201853 Frei zugänglicher VolltextQuelle: OpenAlex

  6. Hepatocellular carcinoma in Turkey: A nationwide health system database analysis of clinical patterns and survival

    Cancer Epidemiology, 2026

    DOI 10.1016/j.canep.2026.103255 PMID 42887435 Quelle: ORCID

  7. The Role of Dominant Lesion Site and SUVmax in the Depth of PSA Response in Metastatic Hormone-Sensitive Prostate Cancer

    Biomedicines, 2026

    DOI 10.3390/biomedicines14102160 PMID 42939968 Frei zugänglicher VolltextQuelle: ORCID

  8. Proton Pump Inhibitor Use and Survival Outcomes in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Immunotherapy: A Real-World Study

    Medicina, 2026

    DOI 10.3390/medicina62071413 PMID 42512955 Frei zugänglicher VolltextQuelle: ORCID

  9. Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study

    In Vivo, 2026

    DOI 10.21873/invivo.14401 PMID 42379805 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  10. Hospitalized oncology patients with diarrhea: Clinical outcomes and prognostic factors.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.11136 Quelle: OpenAlex

  11. Pathologic response in relation to total neoadjuvant therapy sequence, completion, and extra consolidation chemotherapy in locally advanced rectal cancer.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.e15648 Frei zugänglicher VolltextQuelle: OpenAlex

  12. Monoallelic germline RAD51C, RAD51D, and BRIP1 variants in hereditary cancer testing: Variant spectrum and clinical counselling implications

    Mutation research. Fundamental and molecular mechanisms of mutagenesis, 2026

    DOI 10.1016/j.mrfmmm.2026.111941 PMID 42322921 Quelle: OpenAlex

  13. Wearable-derived postdischarge mobility as a digital biomarker for 90-day readmission and mortality in metastatic cancer

    Supportive Care in Cancer, 2026

    DOI 10.1007/s00520-026-11216-6 PMID 42726154 Quelle: OpenAlex

  14. Real-world treatment patterns and prognostic indicators in upper tract urothelial carcinoma: A Turkish Oncology Group (TOG) study

    European Urology Open Science, 2025

    DOI 10.1016/s2666-1683(25)01751-3 Frei zugänglicher VolltextQuelle: OpenAlex

  15. CALLY index as an independent predictor of pathological complete response in HER2-positive breast cancer receiving neoadjuvant therapy

    Clinical and Translational Oncology, 2025

    DOI 10.1007/s12094-025-04077-8 PMID 41091451 8 Zitationen (Europe PMC) Quelle: ORCID

  16. The Accuracy and Sensitivity of Delta Neutrophil Index in Malignancy: Diagnostic Study of Different Types

    Diagnostics, 2025

    DOI 10.3390/diagnostics15243187 PMID 41464189 Frei zugänglicher VolltextQuelle: OpenAlex

  17. A CASE REPORT OF NON-SMALL CELL LUNG CANCER PRESENTED WITH METASTATIC SUBCUTANEOUS NODULE ON BREAST SKIN AND COEXISTING SECOND PRIMARY INVASIVE BREAST CANCER WITHIN THE SAME BREAST

    2024

    DOI 10.22541/au.172444784.41256739/v1 Frei zugänglicher VolltextQuelle: OpenAlex

  18. Clinicopathological Features and First-Line Treatment Outcomes of Geriatric Patients With Extensive-Stage Small Cell Lung Cancer: A Multicenter Study

    Cureus, 2023

    DOI 10.7759/cureus.35710 PMID 36875256 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  19. Lorlatinib-Related Vision Loss: Two Cases of Non-Small Cell Lung Cancer with Blindness

    Journal of Oncological Sciences, 2023

    DOI 10.37047/jos.2022-92714 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  20. Onkolojide Moleküler Hedefli Tedaviler

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1478 Frei zugänglicher VolltextQuelle: OpenAlex

  21. Toraks Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1073 Frei zugänglicher VolltextQuelle: OpenAlex

  22. Evaluation of caregiver burden of cancer patients and impact of this burden on caregiver's quality of life

    Journal of Health Sciences and Medicine, 2022

    DOI 10.32322/jhsm.1025215 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  23. Pancreatic cancer treatment after FOLFIRINOX: prognostic importance of chemotherapy dose intensity and albumin/globulin ratio in second line

    Journal of Health Sciences and Medicine, 2022

    DOI 10.32322/jhsm.1011658 Frei zugänglicher VolltextQuelle: ORCID

  24. Evaluation of cancer patients receiving concurrent chemotherapy and antituberculosis treatment: Review and case series of a single-center experience

    Journal of Surgery and Medicine, 2022

    DOI 10.28982/josam.1015461 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  25. Medical Oncology or Surgical Oncology: Which Branch Should Be Started in Esophageal Cancer Diagnostic Evaluation?

    Cureus, 2022

    DOI 10.7759/cureus.22286 PMID 35350502 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  26. Roles of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT, CA19-9 levels, and complete blood count parameters in predicting survival in patients with unresectable or metastatic pancreatic cancer.

    PubMed, 2022

    PMID 35166229 1 Zitation (OpenAlex) Quelle: OpenAlex

  27. Prognostic Markers in the Treatment of Abiraterone Acetate + Prednisolone and Enzalutamide in Castration-Resistant Metastatic Prostate Cancer

    Eurasian Journal of Medical Investigation, 2022

    DOI 10.14744/ejmi.2022.22832 Quelle: OpenAlex

  28. Gastrointestinal Sistem Tümörleri-2

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1212 Frei zugänglicher VolltextQuelle: OpenAlex

  29. The role of inflammatory parameters in predicting disease recurrence in patients with stage IIA colon cancer with no high-risk features

    Postgraduate Medicine, 2021

    DOI 10.1080/00325481.2021.1934493 PMID 34030576 2 Zitationen (Europe PMC) Quelle: ORCID

  30. Nivolumab-Related Dry Mouth and Dry Eye: Cross-Sectional Study

    Cancer Investigation, 2021

    DOI 10.1080/07357907.2021.1971241 PMID 34415812 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  31. Depression and anxiety in cancer patients before and during the SARS-CoV-2 pandemic: association with treatment delays

    Quality of Life Research, 2021

    DOI 10.1007/s11136-021-02795-4 PMID 33635508 38 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  32. Evaluation of caregiver burden, and quality of life in metastatic prostate cancer patients and caregivers; Effects of clinical and socioeconomic factors

    2021

    DOI 10.21203/rs.3.rs-359207/v1 Frei zugänglicher VolltextQuelle: ORCID

  33. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT

    Annals of Nuclear Medicine, 2021

    DOI 10.1007/s12149-021-01616-5 PMID 33934311 162 Zitationen (OpenAlex) Quelle: OpenAlex

  34. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients

    Annals of Nuclear Medicine, 2021

    DOI 10.1007/s12149-021-01594-8 PMID 33586097 8 Zitationen (OpenAlex) Quelle: OpenAlex

  35. Role of 68Ga-PSMA PET/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment.

    PubMed, 2021

    DOI 10.1967/s002449912303 PMID 33866336 6 Zitationen (OpenAlex) Quelle: OpenAlex

  36. Evaluation of caregiver burden and quality of life in metastatic prostate cancer patients; Effects of clinical and socioeconomic factors

    Dicle Medical Journal / Dicle Tip Dergisi, 2021

    DOI 10.5798/dicletip.1037634 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  37. Multimodality Treatment For Peritoneal Mesothelioma: A Single Center Experience

    Acta Oncologica Turcica, 2020

    DOI 10.5505/aot.2020.71931 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

  38. Short term real world safety data of pertuzumab use in HER2 targeted treatment of metastatic breast cancer

    Journal of Oncological Sciences, 2018

    DOI 10.1016/j.jons.2017.12.002 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID